WHO FCTC Announces Opening of COP10

2Firsts Events by 2FIRSTS.ai
Feb.06.2024
WHO FCTC Announces Opening of COP10
The World Health Organization Framework Convention on Tobacco Control (WHO FCTC) announces the opening of its 10th Conference of Parties (COP10).

The 10th Conference of the Parties (COP10) of the World Health Organization Framework Convention on Tobacco Control (WHO FCTC) was officially announced on the organization's website on February 5th.

 

The 183 signatories of this convention, representing over 90% of the global population, are collectively working to strengthen and promote tobacco control. Despite the ongoing global population growth in the first two decades of this century, the smoking rate among adults has dropped from nearly 33% to 22%.

 

Dr. Adriana Blanco Marquizo, Director of the Secretariat of the WHO Framework Convention on Tobacco Control, welcomed the participants and raised concerns about the growing prevalence of emerging nicotine and tobacco products.

 

She pointed out that these products "have become a concerning issue, with young people rapidly increasing their usage. One of the reasons is the tobacco industry's misleading information, portraying these products as substitutes for real tobacco control measures. The tobacco industry is once again trying to gain a foothold in addressing the epidemic problem it created and continues to perpetuate.

 

She further urged everyone to be vigilant about the relentless interference of the tobacco industry worldwide, highlighting that "the tobacco industry is attempting to undermine not just COP10, but the efforts of every Conference of the Parties.

 

The Conference of the Parties (COP) is the decision-making body of the World Health Organization Framework Convention on Tobacco Control, comprising of all the treaty's signatories. It regularly reviews the implementation of the convention and makes necessary decisions to promote its effective implementation.

 

The conference will consider a range of actions to guide future work on addressing the global tobacco epidemic, which annually claims the lives of 8.7 million people worldwide, in line with the World Health Organization's Framework Convention on Tobacco Control.

 

The discussion topics at COP10 include:

 

  • Implementation of Articles 9 and 10 of the WHO Framework Convention on Tobacco Control (Regulation of Tobacco Product Ingredients and Disclosure): Report Presented by the Bureau, Expert Group, and WHO  
  • Tobacco Advertising, Promotion, and Sponsorship: Depictions of Tobacco in Entertainment Media: Report Presented by the Working Group  
  • NTPs and Emerging Tobacco Products  
  • Future Tobacco Control Measures (Related to Article 2.1 of the WHO Framework Convention on Tobacco Control)  
  • Implementation of Article 19 of the WHO Framework Convention on Tobacco Control: Responsibilities  
  • Improving the Reporting System of the WHO Framework Convention on Tobacco Control  
  • Implementation Review Mechanism  
  • Contribution of the WHO Framework Convention on Tobacco Control to the Promotion and Realization of Human Rights  
  • WHO Framework Convention on Tobacco Control Investment Fund

Furthermore, discussions on the tobacco control investment fund and the upcoming COP10, scheduled to run from today until Saturday, February 10th, are expected. Following that, the Third Meeting of the Parties to the Protocol to Eliminate Illicit Trade in Tobacco Products (MOP3) is set to take place from Monday, February 12th, to Thursday, February 15th, 2024.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

UK Vape Tax Countdown: Retailer Vape HQ Estimates 100ml E-liquid Prices Could Rise From £12.99 to £39.39, While Pod Kits Increase Less Than 10%
UK Vape Tax Countdown: Retailer Vape HQ Estimates 100ml E-liquid Prices Could Rise From £12.99 to £39.39, While Pod Kits Increase Less Than 10%
The UK’s Vaping Products Duty (VPD), scheduled to take effect in October 2026, is prompting retailers to assess how different vape categories may be affected. UK retailer Vape HQ has estimated potential price changes under the new volume-based tax system, showing that 100ml shortfill e-liquids could see prices rise from around £12.99 to £39.39, a 203% increase, while 2ml prefilled pod vape kits could rise from £5.99 to £6.52, an increase of about 9%. The estimates highlight how a volume-based tax structure creates uneven cost impacts across product categories.
Aug.19
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Asia Manufacturing Corp. has invested ₱2.1 billion, or about $37 million, in its manufacturing site in Malvar, Batangas, Philippines, to expand tobacco-processing capabilities. About ₱1.9 billion is allocated to JTI's first Dry Ice Expanded Tobacco, or DIET, facility in Southeast Asia, while more than ₱177 million has been spent on expanding its Controlled Atmosphere treatment facility. The Batangas plant supplies the Philippine market and exports to 22 overseas markets, making it one of JTI's key manufacturing hubs in Asia.
Sep.24
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
Ahead of the Formula 1 race in Madrid, 67 Spanish and international public-health, medical and consumer organizations have sent an open letter to F1 President and CEO Stefano Domenicali calling for an end to sponsorships linked to the tobacco and nicotine industry, including nicotine pouches, vaping products and heated tobacco. The letter focuses on Philip Morris International’s ZYN partnership with Ferrari and British American Tobacco’s long-running partnership with McLaren and exposure for VELO. The campaign follows a March letter in which more than 160 organizations worldwide made a similar request to Formula 1.
Sep.10